{Reference Type}: Journal Article
{Title}: Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology.
{Author}: Würnschimmel C;Menges D;Kwiatkowski M;Sigg S;Prause L;Mattei A;Engeler D;Eberli D;Seifert H;Valerio M;Rentsch CA;Mortezavi A;
{Journal}: Swiss Med Wkly
{Volume}: 154
{Issue}: 0
{Year}: 2024 May 31
暂无{DOI}: 10.57187/s.3626
{Abstract}: Over a decade ago, the United States Preventive Services Taskforce (USPSTF) recommended against prostate-specific antigen (PSA)-based screening for prostate cancer in all men, which considerably influenced prostate cancer screening policies worldwide after that. Consequently, the world has seen increasing numbers of advanced stages and prostate cancer deaths, which later led the USPSTF to withdraw its initial statement. Meanwhile, the European Union has elaborated a directive to address the problem of implementing prostate cancer screening in "Europe's Beating Cancer Plan". In Switzerland, concerned urologists formed an open Swiss Prostate Cancer Screening Group to improve the early detection of prostate cancer. On the 20th of September 2023, during the annual general assembly of the Swiss Society of Urology (SGU/SSU) in Lausanne, members positively voted for a stepwise approach to evaluate the feasibility of implementing organised prostate cancer screening programs in Switzerland. The following article will summarise the events and scientific advances in the last decade during which evidence and promising additional modalities to complement PSA-based prostate cancer screening have emerged. It also aims to provide an overview of contemporary strategies and their potential harms and benefits.